PL338423A1 - Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4 - Google Patents

Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4

Info

Publication number
PL338423A1
PL338423A1 PL98338423A PL33842398A PL338423A1 PL 338423 A1 PL338423 A1 PL 338423A1 PL 98338423 A PL98338423 A PL 98338423A PL 33842398 A PL33842398 A PL 33842398A PL 338423 A1 PL338423 A1 PL 338423A1
Authority
PL
Poland
Prior art keywords
leucocytes
vla
mediation
compounds
type capable
Prior art date
Application number
PL98338423A
Original Assignee
Elan Pharm Inc
American Home Prod
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc, American Home Prod filed Critical Elan Pharm Inc
Publication of PL338423A1 publication Critical patent/PL338423A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
PL98338423A 1997-07-31 1998-07-30 Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4 PL338423A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92039497A 1997-07-31 1997-07-31

Publications (1)

Publication Number Publication Date
PL338423A1 true PL338423A1 (en) 2000-11-06

Family

ID=25443662

Family Applications (1)

Application Number Title Priority Date Filing Date
PL98338423A PL338423A1 (en) 1997-07-31 1998-07-30 Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4

Country Status (16)

Country Link
EP (1) EP1001972A1 (en)
JP (1) JP2001512134A (en)
KR (1) KR20010022411A (en)
CN (1) CN1133648C (en)
AR (1) AR013384A1 (en)
AU (1) AU756696B2 (en)
BR (1) BR9812114A (en)
CA (1) CA2290747A1 (en)
HU (1) HUP0004259A3 (en)
IL (1) IL133640A0 (en)
NO (1) NO20000450L (en)
NZ (1) NZ502582A (en)
PL (1) PL338423A1 (en)
TW (1) TW534910B (en)
WO (1) WO1999006431A1 (en)
ZA (1) ZA986827B (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6291511B1 (en) 1997-05-29 2001-09-18 Merck & Co., Inc. Biarylalkanoic acids as cell adhesion inhibitors
US6903075B1 (en) 1997-05-29 2005-06-07 Merck & Co., Inc. Heterocyclic amide compounds as cell adhesion inhibitors
US6093696A (en) * 1997-05-30 2000-07-25 Celltech Therapeutics, Limited Tyrosine derivatives
US6482849B1 (en) 1997-06-23 2002-11-19 Tanabe Seiyaku Co., Ltd. Inhibitors of α4β1 mediated cell adhesion
US6197794B1 (en) * 1998-01-08 2001-03-06 Celltech Therapeutics Limited Phenylalanine derivatives
MY153569A (en) 1998-01-20 2015-02-27 Mitsubishi Tanabe Pharma Corp Inhibitors of ?4 mediated cell adhesion
US6329372B1 (en) 1998-01-27 2001-12-11 Celltech Therapeutics Limited Phenylalanine derivatives
ES2226413T3 (en) 1998-02-26 2005-03-16 Celltech Therapeutics Limited PHENYLALANINE DERIVATIVES AS INTEGRIN ALFA-4 INHIBITORS.
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9811159D0 (en) * 1998-05-22 1998-07-22 Celltech Therapeutics Ltd Chemical compounds
GB9811969D0 (en) 1998-06-03 1998-07-29 Celltech Therapeutics Ltd Chemical compounds
US6685617B1 (en) 1998-06-23 2004-02-03 Pharmacia & Upjohn Company Inhibitors of α4β1 mediated cell adhesion
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
US6333340B1 (en) * 1998-08-14 2001-12-25 Gpi Nil Holdings, Inc. Small molecule sulfonamides for vision and memory disorders
US6339101B1 (en) * 1998-08-14 2002-01-15 Gpi Nil Holdings, Inc. N-linked sulfonamides of N-heterocyclic carboxylic acids or isosteres for vision and memory disorders
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9821222D0 (en) 1998-09-30 1998-11-25 Celltech Therapeutics Ltd Chemical compounds
US7396526B1 (en) 1998-11-12 2008-07-08 Johnson & Johnson Consumer Companies, Inc. Skin care composition
GB9825652D0 (en) 1998-11-23 1999-01-13 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
US6545003B1 (en) 1999-01-22 2003-04-08 Elan Pharmaceuticals, Inc. Fused ring heteroaryl and heterocyclic compounds which inhibit leukocyte adhesion mediated by VLA-4
KR100711840B1 (en) 1999-01-22 2007-05-02 엘란 파마슈티칼스, 인크. Acyl derivatives which treat VLA-4 related disorders
US6436904B1 (en) 1999-01-25 2002-08-20 Elan Pharmaceuticals, Inc. Compounds which inhibit leukocyte adhesion mediated by VLA-4
CN1185250C (en) * 1999-01-25 2005-01-19 依兰制药公司 Compounds which inhibit leukocyte adhesion mediated by VLA-4
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
ATE343383T1 (en) * 1999-08-13 2006-11-15 Biogen Idec Inc CELL ADHESION INHIBITORS
US6534513B1 (en) 1999-09-29 2003-03-18 Celltech R&D Limited Phenylalkanoic acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
KR20020067050A (en) 1999-12-28 2002-08-21 화이자 프로덕츠 인코포레이티드 Non-peptidyl inhibitors of vla-4 dependent cell binding useful in treating inflammatory, autoimmune, and respiratory diseases
WO2001079173A2 (en) 2000-04-17 2001-10-25 Celltech R & D Limited Enamine derivatives as cell adhesion molecules
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1301488A1 (en) 2000-07-07 2003-04-16 Celltech R&D Limited Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists
AU2001275724A1 (en) 2000-08-02 2002-02-13 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
CZ302653B6 (en) 2000-08-18 2011-08-17 Ajinomoto Co., Inc. Phenylalanine derivatives, alpha-4-integrin antagonist, therapeutic agent or prophylactic agent and pharmaceutical composition in which the derivatives are comprised
MY129000A (en) 2000-08-31 2007-03-30 Tanabe Seiyaku Co INHIBITORS OF a4 MEDIATED CELL ADHESION
US6607735B2 (en) 2000-12-21 2003-08-19 Johnson & Johnson Consumer Companies, Inc. Method for reducing the appearance of dark circles under the eyes
JP2004526733A (en) * 2001-03-20 2004-09-02 メルク　エンド　カムパニー　インコーポレーテッド Substituted N-arylsulfonyl-proline derivatives as potent cell adhesion inhibitors
DE10127126A1 (en) * 2001-06-05 2002-12-19 Forschungszentrum Juelich Gmbh New protected O-(2-substituted ethyl)-L-tyrosine derivatives, useful as intermediates for the positron emission tomography contrast agent O-(2-(18F)-fluoroethyl)-L-tyrosine
MY140707A (en) 2002-02-28 2010-01-15 Mitsubishi Tanabe Pharma Corp Process for preparing a phenylalanine derivative and intermediates thereof
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
TWI281470B (en) 2002-05-24 2007-05-21 Elan Pharm Inc Heterocyclic compounds which inhibit leukocyte adhesion mediated by alpha4 integrins
MXPA05007823A (en) * 2003-01-24 2005-10-18 Elan Pharm Inc Composition for and treatment of demyelinating diseases and paralysis by administration of remyelinating agents.
EP1635822A4 (en) * 2003-06-25 2009-06-24 Elan Pharm Inc Methods and compositions for treating rheumatoid arthritis
ES2548853T3 (en) 2003-12-22 2015-10-21 Ajinomoto Co., Inc. Phenylalanine derivative
US20100150915A1 (en) 2007-02-20 2010-06-17 Stewart Edward J Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
ES2525065T3 (en) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Human serum albumin linkers and their conjugates
WO2010012650A1 (en) * 2008-07-28 2010-02-04 Syddansk Universitet Compounds for the treatment of metabolic diseases
EP3116910A1 (en) 2014-03-13 2017-01-18 Prothena Biosciences Limited Combination treatment for multiple sclerosis
CA3114240C (en) 2018-10-30 2023-09-05 Gilead Sciences, Inc. Imidazopyridine derivatives as alpha4beta7 integrin inhibitors
SG11202103484RA (en) 2018-10-30 2021-05-28 Gilead Sciences Inc Quinoline derivatives as alpha4beta7 integrin inhibitors
CN112969504B (en) 2018-10-30 2024-04-09 吉利德科学公司 Compounds for inhibiting alpha 4 beta 7 integrin
JP7189368B2 (en) 2018-10-30 2022-12-13 ギリアード サイエンシーズ， インコーポレイテッド Compounds for inhibition of alpha4beta7 integrin
CA3148613A1 (en) 2019-08-14 2021-02-18 Gilead Sciences, Inc. Phenylalanine derived compounds and their use as inhinitors of alpha 4 beta 7 integrin

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA737898B (en) * 1972-11-24 1974-07-31 Hoffmann La Roche Peptides
CA1102316A (en) * 1975-12-09 1981-06-02 Shosuke Okamoto N su2 xx-arylsulfonyl-l-argininamides and the pharmaceutically acceptable salts thereof
WO1992016549A1 (en) * 1991-03-18 1992-10-01 Pentapharm Ag Parasubstituted phenylalanine derivates
WO1995015973A1 (en) * 1993-12-06 1995-06-15 Cytel Corporation Cs-1 peptidomimetics, compositions and methods of using the same
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors

Also Published As

Publication number Publication date
AU8661198A (en) 1999-02-22
CN1265668A (en) 2000-09-06
NO20000450D0 (en) 2000-01-28
WO1999006431A1 (en) 1999-02-11
KR20010022411A (en) 2001-03-15
CN1133648C (en) 2004-01-07
AU756696B2 (en) 2003-01-23
HUP0004259A3 (en) 2001-05-28
JP2001512134A (en) 2001-08-21
CA2290747A1 (en) 1999-02-11
TW534910B (en) 2003-06-01
NZ502582A (en) 2002-07-26
IL133640A0 (en) 2001-04-30
EP1001972A1 (en) 2000-05-24
BR9812114A (en) 2000-07-18
NO20000450L (en) 2000-03-28
ZA986827B (en) 2000-05-02
HUP0004259A2 (en) 2001-04-28
AR013384A1 (en) 2000-12-27

Similar Documents

Publication Publication Date Title
PL338423A1 (en) Compounds of substituted phenylamine type capable to inhibit adhesion of leucocytes through the mediation of vla-4
PL338506A1 (en) Compounds inhibiting adhesion of leucocytes occuring through the mediation of vla-4
PL338521A1 (en) Carbamyloxylic compounds inhibiting adhesion of leucocytes occurring through the mediation of vla-4
PL338510A1 (en) Benzyl compounds inhinbiting the adhesion of leucocytes occurring through the mediation of vla-4
PL338457A1 (en) Sulphonylated dipeptidic compounds capable to inhibit adhesion of leucocytes through the mediation of vla-4
PL338554A1 (en) Dipeptidic compounds inhibiting adhesion of leucocytes occurring through the mediation of vla-4
PL338373A1 (en) Dipeptide and its affinite compounds inhibiting adhesion of leucocytes occurring through mediation of vla-4
IL133638A0 (en) 4-amino-phenylalanine type compounds which inhibit leukocyte adhesion mediated by vla-4
AU3102797A (en) Cell adhesion inhibiting compounds
AU1813599A (en) Improvements relating to the bayer process
GB9712253D0 (en) Antiviral compound
GB9706377D0 (en) Novel compound
PL315813A1 (en) Tetrahydropyrimidines as agents effective against arthropods
GB9714143D0 (en) Improvements relating to fastening devices
GB9520145D0 (en) Improvements relating to fastening devices
ZA937265B (en) Laminating construction adhesive compositions with improved performance
GB2323142B (en) Improvements relating to fastening systems
AUPP407598A0 (en) Improvements relating to threaded fastening systems
GB9706178D0 (en) Novel compound
GB9705451D0 (en) Novel compound
GB9716927D0 (en) Novel compound
GB9707872D0 (en) Novel compound
GB9706335D0 (en) Novel compound
GB9704158D0 (en) Novel compound
GB9705614D0 (en) Novel compound

Legal Events

Date Code Title Description
VDSO Invalidation of derivated patent or utility model

Ref document number: 375244

Country of ref document: PL